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The eﬀects of two valerian extracts (aqueous and hydroalcoholic) were investigated through [3H]Glutamate ([3H]Glu) and
[3H]Fluorowillardine ([3H]FW) receptor binding assays using rat synaptic membranes in presence of diﬀerent receptor ligands.
In addition, the extract stability was monitored spectrophotometrically. Both extracts demonstrated interaction with ionotropic
glutamate receptors (iGluRs). However, the extracts displayed considerable diﬀerences in receptor selectivity. The hydroalcoholic
extract selectively interacted with quisqualic acid (QA), group I metabotropic glutamate receptor (mGluR) ligand, while the
aqueous extract did not alter the binding of QA. The stability of the extracts was examined during several weeks. Freshly prepared
extract inhibited 38–60% of [3H]FW binding (AMPA). After 10 days, the aqueous extract inhibited 85% of [3H]FW binding
while the hydroalcoholic extract markedly potentiated (200%) [3H]FW binding to AMPA receptors. Thus, our results showed that
factors such as extraction solvent and extract stability determine the selectivity for glutamate receptor (GluR) interactions.
1.Introduction
Valeriana oﬃcinalis, commonly known as Valerian, is one of
approximately 250 Valerian species from the Valerianaceae
family, and it is used for the preparation of phytomedicines
with sedative, anxiolytic, and spasmolytic properties. The
therapeutic beneﬁts of Valerian have always been in con-
troversy due to the inconsistent clinical results [1–3].
The discrepancies among clinical trials may be due to
methodological limitations and diﬀerences in the Valerian
preparations (method of extraction and extraction solvent).
Many studies use water as the extraction solvent because
traditionally natural product preparations (i.e., tea) are
preparedinwater .A queousextractsofV alerianhavediﬀerent
spectrum of active constituents than extracts that have been
processed with ethanol [4].
The speciﬁc mechanism(s) of action responsible for the
pharmacological eﬀects of Valerian root extracts have not
been fully elucidated although it is thought that Valerian
root extracts stimulate the GABA transmission [2, 3, 5–10].
On the other hand, few studies have investigated the eﬀects
of Valeriana oﬃcinalis in the excitatory glutamate-mediated
neurotransmission [11].
Based on these studies, the possible eﬀects of Valerian
extracts on glutamate-mediated (excitatory) neurotransmis-
sion were assessed using receptor binding assays with rat
synaptic membranes in presence of aqueous and hydroalco-
holic Valerian extracts and glutamate receptors ligands (MK-
801 for NMDA, AMPA or [3H]Fluorowillardiine for AMPA,
kainic acid for KA, and quisqualic acid (QA) for Group I
metabotropic glutamate receptors (mGluRs)).
2.MaterialsandMethods
2.1. Chemicals. L-[2,3,4-3H]-Glutamic acid (60Ci/mmol)
and [3H]Fluorowiillardiine (80Ci/mmol) were obtained
from American Radiolabeled Chemicals, Inc (St. Louis,
MO). AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionic acid) was obtained from Tocris Cookson, Inc.
(Ellisville, MO). Potassium Chloride was purchased from2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of diﬀerent fresh Valerian extracts (1mg/mL) on [3H]Glutamate binding to rat synaptic membranes in the presence of
1mM glutamate receptor (GluR) ligands. (a) The aqueous extract decreases the eﬀects of the NMDA (MK-801), AMPA, and Kainate (KA),
but it did not alter the eﬀects of quisqualic acid (QA), a group I metabotropic glutamate receptor (mGluR) ligand. (b) The hydroalcoholic
extract also decreases the eﬀects of NMDA, AMPA, and KA. In contrast, Valerian reverses the inhibitory eﬀects of QA. +agonist versus agonist
+V a l e r i a n ,P<. 05; ++P<. 01; +++P<. 001.
Matheson Coleman & Bell (Norwood, OH). UniverSol ES
was obtained from MP Biomedicals (Solon, OH). All other
reagents were obtained from Sigma Chemical Company (St.
Louis, MO).
2.2. Valerian Extracts. Organically grown and certiﬁed Vale-
rian dry powdered roots (Lot. 1111H-OUP), harvested in
2004, were obtained from Paciﬁc Botanicals (LLC Grants
Pass, Oregon). Commercial Valerian. Nature’s Resources
Extract (Lot. LD11282N) and Nature’s Resource Herb (Lot.
MG11258) were purchased from a local pharmacy. Valerian
was extracted in ultra pure water or ethyl alcohol (EtOH)
70% (1:10w/v) at ∼23◦C, stirred for 1hour, and ﬁltered
through a 12.5cm Whatman Qualitative no. 1 ﬁlter. Aliquots
were centrifuged at 6,700gt or e m o v ep a r t i c u l a t e sa n ds t o r e d
at 4◦C.
2.3. Cerebral Cortex Synaptic Membranes. Analytical Biolog-
ical Services, Inc. (Wilmington, DE) prepared the synaptic
membranes as follows: female rats of approximately two
months of age were decapitated and the brain promptly
removed. The cortex was dissected and homogenized
(1:10w/v) in ice-cold 10mM Tris-HCl buﬀer pH 7.4. The
homogenate was centrifuged twice at 2,500g for 10min. The
resulting supernatant was centrifuged at 12,500g for 20min.
The pellet was washed twice with ice-cold 10mM Tris-
HCl buﬀer pH 7.4 (1:10w/v) and centrifuged at 12,500g
for 20min. The pellet (synaptical membrane, P2) was
resuspended in 10mM Tris-HCl buﬀer pH 7.4 and freeze
thawed at least three times before being stored at −80◦C
until used. Protein concentration was determined using the
Bradford assay [12] using bovine serum albumin (BSA) as
reference standard.
2.4. Receptor Binding Assays
2.4.1. [3H]Glutamate Binding. Receptor binding competi-
tion assays were done using synaptic membranes of cerebral
cortexfromAnalyticalBiologicalServices,Inc.(Wilmington,
DE). The reaction was initiated by the addition of tissue
(100μg protein) to tubes containing 1mM of (MK-801 for
NMDA, AMPA, kainic acid for KA, and quisqualic acid (QA)
for Group I metabotropic glutamate receptors (mGluR) and
20nM [3H]Glutamic Acid ([3H]Glu) in a ﬁnal volume of
500μL of 50mM Tris HCl/100mM KCl buﬀer, pH 7.4). The
nonspeciﬁc binding was determined in the presence of 1mM
nonradioactive glutamate. Total binding was determined in
the presence of Valerian extracts in diﬀerent solvents (H2O
and EtOH) in order to do competition studies. All samples
were incubated on ice (0–4◦C) for 40minutes. The assay
was stopped by centrifugation for 30min at 6,764g; the
supernatant was extracted and the pellet washed two times
with 1mL of ice-cold buﬀer. The pellet was resuspended in
500μLo fb u ﬀer. Radioactivity of the samples was quantiﬁed
in a Beckman LS 6500 Multipurpose Scintillation Counter
with 1mL of UniverSol ES scintillation cocktail. Results are
shown as percentage of total binding (±SEM).
2.4.2. [3H]Fluorowillardine Binding. Assays were done using
synaptic membranes of cerebral cortex from Analytical
Biological Services, Inc. (Wilmington, DE). The reaction was
initiated by the addition of tissue (100μg protein) to tubes
containing 15nM [3H] Fluorowillardine ([3H]FW) in a ﬁnal
volume of 500μLo f5 0 m MT r i sH C l / 1 0 0 m MK C lb u ﬀer,
pH 7.4. Nonspeciﬁc binding was determined in the presence
of 10mM glutamate. Total binding was determined in the
presence of Valerian extracts in diﬀerent solvents (H2Oa n dEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Changes in 3[H]Fluorowillardine binding with time.
Initially, a 60% of inhibition is observed with the aqueous extracts
while the hydroalcoholic extract inhibits only a 38%. However, with
time, the inhibitory eﬀects of the aqueous extract increase to 85%
whereas the hydroalcoholic extract markedly potentiates (200%)
3[H]Fluorowillardine ([3H]FW) binding to AMPA receptors.
EtOH) in order to do competition studies. All samples were
incubated on ice (0–4◦C) for 40minutes. The assay was
stopped by centrifugation for 30min at 6,764g. Then, the
supernatant was removed and the pellet washed two times
with 1mL of ice-cold buﬀer. The pellet was resuspended in
500μLo fb u ﬀer. Radioactivity of the samples was quantiﬁed
in a Beckman LS 1800 counter with 1mL of UniverSol
scintillation cocktail. Results are shown as percentage of total
binding (±SEM).
2.5. Wavelength Scans. Spectrophotometric analyses were
done with a Beckman DU Series 500 Spectrophotometer
(Fullerton, CA). A volume of 1mL of 10mg/mL Valerian
extract was placed in Elkay Ultra-Vu Disposable Cuvettes
from Elkay Products, Inc. (Shrewsbery, MA). The scans were
done from 190nm to 320nm in steps of 1.0nm.
2.6. Statistical Analysis. Data are expressed as mean values
± the standard error of the mean (SEM) of at least
three experiments. The diﬀerences between the experimental
groups were tested for signiﬁcance using one way analysis of
variance followed by Tukey-Kramer Multiple Comparisons
Test, with P<. 05. Statistics for the experimental group
versus total binding are not shown for clarity.
3. Results
3.1. Extraction Solvents Change Ligand Binding to Glutamate
Receptors. Figure 1 shows the eﬀects of diﬀerent Valerian
extracts (1mg/mL) on [3H]Glutamate binding to rat synap-
tic membranes in the presence of 1mM GluR ligands
(NMDA, AMPA, KA, or QA). The aqueous extract (a)
decreases the eﬀects of the NMDA (MK-801), AMPA, and
kainate (KA), but it did not alter the eﬀects of quisqualic acid
(QA), a Group I metabotropic glutamate receptor (mGluR)
ligand. The hydroalcoholic extract (b) has similar eﬀects as
the aqueous extracts on NMDA, AMPA, and KA treated
membranes. However, the hydroalcoholic extract potentiates
the eﬀects of QA, suggesting a strong eﬀect on group I
mGluR.
Similarly, the eﬀects of aqueous and hydroalcoholic
extracts on AMPA were evaluated by binding assays using
[3H]FW. Initially, the aqueous and hydroalcoholic extracts
(Figure 2) have 60% and 38% inhibitory eﬀects on [3H]FW
binding, respectively. However, with time (4 weeks), the
aqueous extract inhibits [3H]FW to 85% while the hydroal-
coholic extract markedly increases [3H]FW binding (200%)
to AMPA receptors.
3.2. Extract Stability Alters Ligand Binding to Glutamate
Receptor. The eﬀect of two Valerian commercial products
(prepared as aqueous extracts) was evaluated on AMPA
binding ([3H]FW). Figure 3 shows the eﬀect of time
in [3H]FW binding. (a) At time zero, Valerian Nature’s
Resource Extract and Nature’s Resource Herb inhibit
[3H]Fluorowillardine binding. (b) After a period of time
(42 days (Extract) or 39 days (Herb)), the extracts loose the
inhibitory eﬀects. Further in time (48 days (Extract) or 45
days (Herb)), they potentiate [3H]Fluorowillardine binding.
3.3. Spectrophotometric Analysis of Aqueous and Hydroal-
coholic Extracts. The spectra of diﬀerent Valerian extracts
(10mg/mL) prepared in H2O and EtOH were evaluated
spectrophotometrically as shown in Figure 4. The insert in
Figure 4 shows a list of wavelength and only two, 292 and
298nm, demonstrate signiﬁcant diﬀerences.
4. Discussion
Valerian is a well-recognized plant used in the folkloric
medicine for its sedative and anxiolytic properties [2].
Numerous studies evaluate the use of Valerian root extracts
to induce and improve sleep quality [13–15] while others
evaluate Valerian anxiolytic eﬀects [16–18]. In humans,
Valerian extracts reduced latency to fall asleep as eﬀectively
as small doses of benzodiazepines [19]. Although Valerian’s
anxiolytic properties are well documented in mice and rats
[20], there is no scientiﬁc evidence that could support the
anxiolytic properties of the plant in humans, due to intrinsic
methodological problems such as variation in Valerian
doses and preparations, number of patients, and length of
treatment [1].4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of time in 3[H]Fluorowillardine binding from two Valerian commercial products. (a) At time zero, aqueous extracts
of Nature’s Resource Extract and Nature’s Resource Herb inhibit [3[H]]Fluorowillardine binding. (b) After a period of time (42 days
(Extract) or 39 days (Herb)), the extracts loose the inhibitory eﬀects. Further in time (48 days (Extract) or 45 days (Herb)), they potentiate
[3[H]]Fluorowillardine binding.
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Figure 4: Spectra and absorbance from aqueous and hydroalcoholic Valerian extracts (10mg/mL). Signiﬁcant diﬀerences at 292 and 298nm
were observed. H2O versus EtOH, P<. 05; ++P<. 01; +++P<. 001.
It is not fully understood which constituents of Valeriana
oﬃcinalis are responsible for the pharmacological actions,
but many manufacturers standardize Valerian preparations
according to the valerenic acid content as recommended
by the German Commission E. Studies suggested that
valerenic acid is the principal active component responsi-
ble for Valerian’s anxiolytic properties [21, 22]. However,
other Valerian constituents such as borneol, lignans, and
ﬂavonoids (hesperidin, linarin, and 6-methylapigenin) have
also been found to have anxiolytic and sedative activity [23–
27]. Moreover, other Valerian species with low valerenic acid
concentration (e.g., Valeriana edulis and Valeriana sitchensis)
have similar pharmacological proﬁles [19, 28–30]. Thus,
there is no evidence showing that valerenic acid is exclusivelyEvidence-Based Complementary and Alternative Medicine 5
Critical factors that aﬀect Valerian’s pharmacological properties
Extraction
solvent
Extraction
stability
Aqueous
extract
Ethanolic
extract
[3H]glutamate binding:
↓ NMDA, AMPA, and KA
= QA (mGluR I)
[3H]glutamate binding:
↓ NMDA, AMPA, and KA
↑↑ QA (mGluR I)
[3H]FW binding:
↓(inhibits) after 30 days
[3H]FW binding:
↑ (potentiates) after 30days
[3H]FW binding:
0d a y s :↓(inhibition)
39–42 days: loose inhibition
45–48 days: potentiation
UV spectra:
signiﬁcant diﬀerences at
292 and 298nm
Figure 5: Summary of the aqueous and ethanolic Valerian extract eﬀects in receptor binding assays and spectrophotometric absorbance.
responsible for the sedative and anxiolytic eﬀects attributed
to Valeriana oﬃcinalis.
Circosta and colleagues [31] conducted the biological
andchemicalcharacterizationoftwoValerianextracts(aque-
ous and hydroalcoholic) and found remarkable diﬀerences
in the content of valepotriates. Similar results were found
by Occhiuto et al. in 2008 [32]. Both studies, from the
same group of researchers, revealed that the phytochemical
analysisofthehydroalcoholicextractandtheaqueousextract
was “similar” in the valerenic acid composition (aqueous
extracts being half of the hydroalcoholic extract content),
but the concentration of the valepotriates was much lower
in the aqueous extract than in the hydroalcoholic extract. In
the biological assays, Circosta and colleagues [31]o b s e r v e d
a lower percent of animals with arrhythmias when the
hydroalcoholic and not the aqueous extracts were given
at a dose of 50mg/kg (80% versus 60%, resp.). Similarly,
Occhiuto et al. [32] reported that the concentration causing
50% inhibition of the amplitude of contractions (uterore-
laxant eﬀect) was 29.5 ± 3.40 and 68.7 ± 5.20μg/mL for the
hydroalcoholic and aqueous extracts, respectively. Therefore,
the biological analysis by these studies demonstrated that
the Valerian extracts possess coronary dilatory, hypotensive,
and bronchodilatory properties as well as relaxing eﬀects
on human myometrial muscle at diﬀerent concentrations;
the hydroalcoholic extracts being always more potent. These
diﬀerences in potency of the hydroalcoholic and aqueous
extractsmayberelatedtodiﬀerencesintheextractionsolvent
and procedure, raw material storage conditions, growing
techniques, harvesting conditions, and age of the plant,
among other factors.
Previously, modest eﬀects of commercial aqueous Vale-
rian extracts on NMDA receptor [3H]MK-801 binding
have been reported [33]. Similarly, Malva and colleagues
[11] reported AMPA-mediated neuroprotective eﬀects of
Valerian. Our experiments show that aqueous and hydroal-
coholic extracts from Valeriana oﬃcinalis have diﬀerent
biological activity as demonstrated by the GluR binding
assays.AqueousandhydroalcoholicValerianextractsinteract
with NMDA, AMPA, and KA receptors. Moreover, Valerian
extracts eﬀects on diﬀerent receptors change with time
as seen with AMPA binding assays. On the other hand,
the aqueous extracts did not have eﬀect in QA while a
strong interaction with group I mGluR is observed with
the hydroalcoholic extracts (see Figure 5). Previous results
from our lab (not shown) had demonstrated that when
valerenic acid was used, as a pure compound, in the same
type of experiments, a similar response (potentiation) was
obtained. These results suggested that the hydroalcoholic
ValerianextractreversestheinhibitoryeﬀectsofQAprobably
due to a higher content of valerenic acid. Further studies
should be done to verify the valerenic acid content in the
diﬀerent extracts.
Previous studies by diﬀerent researchers suggest that
mGluR may have an important role in anxiety [34–36].
In particular, there is evidence involving group II mGluR
(mGlu2/3) and group I mGluR (mGlu5) receptor agonists as
potential anxiolytic agents [37, 38]. This mGluR role could
suggest a possible mechanism by which Valerian extracts
produce their eﬀects. A more detailed study of these Valerian
interactions with mGluR is being examined by our lab.
Navarrete et al. (2006) [29]u s e dH P L Ca n dd e t e c t i o n
at diﬀerent wavelengths to identify Valerian components
(i.e., chlorogenic acid, lignans, ﬂavonoids, valerenic acids,
and valepotriates) in diﬀerent species. Similarly, we screened
for possible spectrographic diﬀerences between the aqueous
and hydroalcoholic extracts. A qualitative analysis of the
absorbance spectra (at diﬀerent wavelengths) of the extracts6 Evidence-Based Complementary and Alternative Medicine
revealed signiﬁcant diﬀerences at 292 and 298nm. Further
studies should be done in order to determine the relation
between spectra changes and binding selectivity.
As u r v e ym a d eb yC o n s u m e r L a b . c o mr e p o r t e dt h a t
4 of 17 Valerian products had no detectable Valerian
compounds, four had half of the expected levels, two
had lead contamination, and one had cadmium contam-
ination (http://www.consumerlab.com)[ 39]. This particu-
lar situation occurred with commercial natural products
manufactured by various processes using diﬀerent solvents.
In addition, the low stability of the compounds, mainly
valepotriates,couldresultintheabsenceofthesecompounds
in the diﬀerent pharmaceutical dosage forms since they
may decompose during the manufacturing process or upon
storage [40].
Products containing Valerian have managed to keep their
place in the natural products market, in spite of the lack
of science based evidence for its eﬃcacy and the strong
competition with synthetic drugs such as benzodiazepines.
Inconsistent and variable pharmacological eﬀects of plant-
derived products are one of the challenges of the natural
products research. Consequently, a drug derived from nat-
ural products could be considered as a rational drug only
if it is standardized and proven to meet the standards of
quality (prove identity, purity, etc.). Biological screening of
plant extracts instead of analysis of individual compound
may be a useful tool in clarifying Valerian pharmacological
eﬀects because of possible synergism as a mechanism of
action(s) of various active compounds. The present study
demonstrates that Valerian extracts interact with the GluR,
and factors such as the extraction solvent and stability of the
extracts are critical to determine changes in selectivity for
GluR interaction.
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